Melancholia

Summary

Melancholia (MONDO:0002444) is a disease and 6 clinical trials. Top therapeutic interventions include fluvoxamine, lamotrigine, and nortriptyline. A subtype of depressive disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	melancholia
Mondo ID	MONDO:0002444
EFO	EFO:1002014
DOID	DOID:2848
NCIT	C34812
UMLS	C0025193
MedGen	6288
Is cancer (heuristic)	no

Also known as: depression with melancholic features · melancholic depression

Disease family

This is a subtype of depressive disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › mental disorder › mood disorder › depressive disorder › melancholia

Related subtypes (6): seasonal affective disorder, major depressive disorder, postpartum depression, bipolar depression, neurotic depression, mixed anxiety and depressive disorder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

1 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Fluvoxamine	Approved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	2
PHASE2	2
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00000378	PHASE4	COMPLETED	Antidepressant Treatment of Melancholia in Late Life
NCT02989727	PHASE4	COMPLETED	Melancholic Symptoms in Bipolar Depression and Responsiveness to Lamotrigine
NCT01548937	PHASE2	COMPLETED	Serotonin Transporter Density in Late-life Depression With and Without Dementia
NCT04160377	PHASE2	UNKNOWN	A Clinical Trial of Fluvoxamine for Melancholia
NCT00971815	Not specified	COMPLETED	Effects of 3 Months of Selective Serotonin Reuptake Inhibitor (SSRI)-Treatment on Metabolism and Hypothalamic-pituitary-adrenal (HPA)-Axis in Young Men Born With Low Birth Weight
NCT03288675	Not specified	COMPLETED	Stepped Care AiTBS 2 Depression Study (Ghent)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
FLUVOXAMINE	4	3
LAMOTRIGINE	4	1
NORTRIPTYLINE	4	1
SERTRALINE	4	1
CHEMBL1788361	0	1